ERBB2 and gastric cancer: A phase Ib/II open-label single-arm trial of trastuzumab in combination with ramucirumab and paclitaxel has recently reported very promising gains in median progression-free (7.1 months, 95% CI: 4.8–9.4) and overall survival (13.6 months, 95% CI: 9.4–17.7) in patients with previously treated metastatic HER2-positive GC (Kim et al., 2023).